PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Three-Pronged attack on tough stomach cancers
Disease control OngoingThis small, early-stage study is testing whether combining an immunotherapy drug (pembrolizumab) with chemotherapy and radiation can help control a type of stomach cancer that cannot be removed by surgery. The goal is to see if this three-part approach is safe and can shrink or e…
Matched conditions: PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Direct-Abdominal chemo tested for tough stomach cancers
Disease control OngoingThis early-stage study is testing whether delivering a chemotherapy drug called paclitaxel directly into the abdominal cavity is safe and tolerable for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The main goal is to find t…
Matched conditions: PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Double-Punch immunotherapy trial aims to wipe out tumors before esophageal cancer surgery
Disease control OngoingThis study is testing whether a powerful combination of treatments can shrink or eliminate tumors before surgery for esophageal and gastroesophageal junction cancers. Patients receive standard chemotherapy and radiation alongside an immunotherapy drug (pembrolizumab), followed by…
Matched conditions: PATHOLOGIC STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC